Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
8.0
4.5
Journals
Cancers
Special Issues
Advances in Colorectal Cancer Survival Analysis
share announcement

Advances in Colorectal Cancer Survival Analysis

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Survivorship and Quality of Life".

Deadline for manuscript submissions: closed (15 July 2023) | Viewed by 4101

Special Issue Editor

Dr. Bogdan Badic

E-Mail Website
Guest Editor
Centre Hospitalier Universitaire de Brest, Brest, France
Interests: cancer

Special Issue Information

Dear Colleagues,

Considerable progress has been made in colorectal cancer research in recent times. Identification of high-risk patients, genetic modifications, chemotherapy regimens and immune therapy for tumors are just a few of the recent discoveries. Every patient and every type of cancer is different, and there are differences within the same cancer in the same patient. New prognostic factors have emerged in terms of prevention, diagnosis, treatment and follow-up of patients with colorectal cancer. The understanding of prognostic inference factors will allow an appropriate treatment strategy but also new research directions. Bringing together in this special issue the latest perspectives in the management of colorectal cancer will facilitate a better management of this disease.

Sincerely,

Dr. Bogdan Badic
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • colorectal cancer
  • survival
  • surgery
  • radiotherapy
  • chemotherapy
  • immune therapy
  • radiomics
  • prevention
  • genomics
  • transcriptomics
  • epidemiology
  • histopathology
  • coagulation factors

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

16 pages, 1746 KiB  
Article
Development and Validation of a Nomogram to Predict Overall Survival in Stage I–III Colorectal Cancer Patients after Radical Resection with Normal Preoperative Serum Carcinoembryonic Antigen
by Xuan Dai, Haoran Wang, Yaqi Lu, Yan Chen, Yun Liu and Shiyong Huang
Cancers 2023, 15(23), 5643; https://doi.org/10.3390/cancers15235643 - 29 Nov 2023
Cited by 1 | Viewed by 867
Abstract
We aimed to develop a clinical predictive model for predicting the overall survival (OS) in stage I–III CRC patients after radical resection with normal preoperative CEA. This study included 1082 consecutive patients. They were further divided into a training set (70%) and a [...] Read more.
We aimed to develop a clinical predictive model for predicting the overall survival (OS) in stage I–III CRC patients after radical resection with normal preoperative CEA. This study included 1082 consecutive patients. They were further divided into a training set (70%) and a validation set (30%). The selection of variables for the model was informed by the Akaike information criterion. After that, the clinical predictive model was constructed, evaluated, and validated. The net reclassification index (NRI) and integrated discrimination improvement (IDI) were employed to compare the models. Age, histologic type, pT stage, pN stage, carbohydrate antigen 242 (CA242), and carbohydrate antigen 125 (CA125) were selected to establish a clinical prediction model for OS. The concordance index (C-index) (0.748 for the training set and 0.702 for the validation set) indicated that the nomogram had good discrimination ability. The decision curve analysis highlighted that the model has superior efficiency in clinical decision-making. NRI and IDI showed that the established nomogram markedly outperformed the TNM stage. The new clinical prediction model was notably superior to the AJCC 8th TNM stage, and it can be used to accurately assess the OS of stage I–III CRC patients undergoing radical resection with normal preoperative CEA. Full article
(This article belongs to the Special Issue Advances in Colorectal Cancer Survival Analysis)
►▼ Show Figures

Figure 1

Review

Jump to: Research

24 pages, 359 KiB  
Review
Radiomics Approaches for the Prediction of Pathological Complete Response after Neoadjuvant Treatment in Locally Advanced Rectal Cancer: Ready for Prime Time?
by Vincent Bourbonne, Ulrike Schick, Olivier Pradier, Dimitris Visvikis, Jean-Philippe Metges and Bogdan Badic
Cancers 2023, 15(2), 432; https://doi.org/10.3390/cancers15020432 - 9 Jan 2023
Cited by 12 | Viewed by 2861
Abstract
In recent years, neoadjuvant therapy of locally advanced rectal cancer has seen tremendous modifications. Adding neoadjuvant chemotherapy before or after chemoradiotherapy significantly increases loco-regional disease-free survival, negative surgical margin rates, and complete response rates. The higher complete rate is particularly clinically meaningful given [...] Read more.
In recent years, neoadjuvant therapy of locally advanced rectal cancer has seen tremendous modifications. Adding neoadjuvant chemotherapy before or after chemoradiotherapy significantly increases loco-regional disease-free survival, negative surgical margin rates, and complete response rates. The higher complete rate is particularly clinically meaningful given the possibility of organ preservation in this specific sub-population, without compromising overall survival. However, all locally advanced rectal cancer most likely does not benefit from total neoadjuvant therapy (TNT), but experiences higher toxicity rates. Diagnosis of complete response after neoadjuvant therapy is a real challenge, with a risk of false negatives and possible under-treatment. These new therapeutic approaches thus raise the need for better selection tools, enabling a personalized therapeutic approach for each patient. These tools mostly focus on the prediction of the pathological complete response given the clinical impact. In this article, we review the place of different biomarkers (clinical, biological, genomics, transcriptomics, proteomics, and radiomics) as well as their clinical implementation and discuss the most recent trends for future steps in prediction modeling in patients with locally advanced rectal cancer. Full article
(This article belongs to the Special Issue Advances in Colorectal Cancer Survival Analysis)
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop